



Clinical Naturopathy 2e

An evidence-based guide to practice




Jerome Sarris &
Jon Wardle

Sample proofs © Elsevier Australia

Clinical Naturopathy 2e

An evidence-based guide to practice

Jerome Sarris & Jon Wardle




Sydney Edinburgh London New York Philadelphia St Louis Toronto

Sample proofs © Elsevier Australia

Contents

Foreword	vii
Preface	x
Acknowledgements	xii
About the editors	xiii
Contributors	xiv
Reviewers	xvii
1 Naturopathic case taking <i>Greg Connolly</i>	1
2 Naturopathic diagnostic techniques <i>Niikee Schoendorfer and Daniel Roytas</i>	19
3 Wellness, lifestyle and preventive medicine <i>Erica Oberg</i>	53
4 Irritable bowel syndrome <i>Jason Hawrelak</i>	73
5 Gastro-oesophageal reflux disease <i>Jason Hawrelak</i>	101
6 Food allergy/intolerance <i>Jane Frawley</i>	118
7 Liver dysfunction and disease <i>Ses Salmond</i>	130
8 Respiratory infections and immune insufficiency <i>David Casteleijn and Tessa Finney-Brown</i>	159
9 Asthma <i>David Casteleijn and Tessa Finney-Brown</i>	183
10 Congestive respiratory disorders <i>David Casteleijn and Tessa Finney-Brown</i>	205
11 Atherosclerosis and dyslipidaemia <i>Michael Alexander</i>	224
12 Hypertension and stroke <i>Michael Alexander</i>	243
13 Chronic venous insufficiency <i>Matthew J Leach</i>	257
14 Anxiety <i>Jerome Sarris</i>	270
15 Depression <i>Jerome Sarris</i>	291
16 Insomnia <i>Jerome Sarris</i>	313
17 Headache and migraine <i>Phillip Cottingham</i>	328
18 Stress and fatigue <i>Tini Gruner and Jerome Sarris</i>	350
19 Diabetes type 2 and insulin resistance <i>Tini Gruner</i>	371
20 Thyroid abnormalities <i>Tini Gruner</i>	399
21 Dysmenorrhoea and menstrual complaints <i>Jon Wardle</i>	423



22	Endometriosis <i>Jon Wardle</i>	439
23	Polycystic ovarian syndrome <i>Jon Wardle</i>	452
24	Menopause <i>Jon Wardle</i>	470
25	Osteoarthritis <i>Paul J Orrock</i>	487
26	Fibromyalgia <i>Leslie Axelrod</i>	507
27	Acne vulgaris <i>Amie Steel</i>	529
28	Inflammatory skin disorders—atopic eczema and psoriasis <i>Amie Steel</i>	543
29	Benign prostatic hypertrophy <i>Kieran Cooley</i>	558
30	Recurrent urinary tract infection <i>Michelle Boyd</i>	578
31	Autoimmune disease <i>Joanne Bradbury and Neville Hartley</i>	593
32	Cancer <i>Janet Schloss</i>	629
33	Paediatrics <i>Vicki Mortimer</i>	655
34	Fertility, preconception care and pregnancy <i>Amie Steel and Karen Martin</i>	673
35	Ageing and cognition <i>Christina Kure</i>	708
36	Bipolar disorder <i>James Lake</i>	731
37	Attention deficit and hyperactivity disorder <i>James Lake</i>	750
38	Chronic fatigue syndrome <i>Gary Deed and Stephanie Gadsden</i>	768
39	Human immunodeficiency virus <i>Jennifer Hillier</i>	789
40	Pain management <i>Justin Sinclair</i>	803
41	Polypharmacy and drug–nutraceutical interactions <i>Justin Sinclair and Christine Sinclair</i>	823
	Appendix 1 Drug–herb interaction chart	839
	Appendix 2 Drug–nutrient interaction chart	845
	Appendix 3 Chemotherapy drugs and concurrent nutraceutical use	852
	Appendix 4 Food sources of nutrients	877
	Appendix 5 Laboratory reference values	879
	Appendix 6 Taxonomic cross-reference of major herbs	887
	Index	895

Foreword

Naturopathy is broadly founded on the concept of creating health and engaging healing through habits of living with respect to natural laws of physiology and through therapeutics that apply the tenets of the healing process within living systems. These tenets are increasingly supported by a wealth of scientific evidence. When I entered the profession in 1978 I was drawn to the field because it clearly was an answer to the repeatedly ineffective healthcare I had personally experienced through ongoing treatment for a condition in which my symptoms were treated with the same substance but without lasting results. During an appointment with two naturopathic doctors-in-training I discovered that they were looking at *reasons* underlying the condition rather than focusing on its symptoms. These doctors asked about lifestyle stress, nutrition and other issues that were maintaining the dysfunctional process in my body. This was indeed an epiphany for me—their approach addressed all aspects of the way we live as human beings: environment, relationships, food, exercise, sleep, inborn susceptibilities and socioeconomic, spiritual and behavioural determinants. The goal was not only for me to be healthy but also for me to recognise that I could not be healthy in unhealthy surroundings. At that moment I realised naturopathy was not a group of therapies; it is a unique approach to how we live that incorporates therapies within a comprehensive framework of tenets to create healthy people in a healthy world. These tenets, now referred to as the naturopathic determinants of health, were originally proposed as a component of the Unity of Cause and Cure theory by Clark (1925) and by Lindlahr (1913) and are synergistic with widely recognised determinants of health promoted within the public health arena. It is gratifying to now witness our international colleagues further elucidate the evidence base supporting these naturopathic tenets central to wellness and health promotion and their practical application with patients. The editors, internationally recognised academic, policy and research leaders Sarris and Wardle, together with their expert authors have done a stellar job organising these evidence-based strategies into a prescriptive approach which moves beyond therapeutic substances and engages the physiological foundations of health to engage increased vitality and thus the healing process, or *vis medicatrix naturae*.

Today, as a naturopathic physician, I remain dedicated to naturopathy's fundamental goal of health creation and its definition of health, which entails a sense of vitality and optimal wellness. Our global healthcare system is progressing slowly towards this unattained vision of health creation (rather than disease management) in people, the world community and the natural environment—all are critical components of the health equation. Yet, we are making progress. In 2000, for instance, while hosting the US Integrative Medicine Industry Leadership Summit, conference chair John Weeks (publisher/editor, Integrator Blog) polled conference participants for their position on this statement: 'Complementary and alternative medicine is a tool of our deeper mission of transformation which will be successful only if we help birth a *thriving industry of health creation*'. Among the 87% of respondents, 84% agreed and nearly 60% 'strongly agreed'. I soon began to recognise health creation tenets within traditional world medicines, within the integrative health and medicine movement and within traditional naturopathy, that now is seeking to re-codify health creation into its textbooks and

curricula (e.g. Pizzorno & Murray's *Textbook of Natural Medicine*, 1999–2012). *Clinical Naturopathy* is an exceptional undertaking and a vital contribution within the rising global tide addressing health creation.

Although the concept of health creation is not new, it generally has evaporated from the purview of healthcare in the last 250 years. In the early 1980s, as I entered clinical practice, the US was at the brink of a burgeoning healthcare crisis recently confirmed by a watershed report from the Institute of Medicine.¹ Despite the population's increased lifespan of 20 years and its enormous expenditure on healthcare, the US nevertheless is now experiencing an astounding decrease in both lifespan and 'healthspan'. Those added 20 years are not healthy years but are burdened by chronic disease and a declining ability of the healthcare system to address these intensified needs. Other nations are experiencing similar statistics. The report cites reasons for this 'health disadvantage'¹ as including health systems, health behaviours, social and economic conditions and physical environments. The National Academy of Sciences has issued a powerful call to action stating that 'we know what to do, and we need to act now'. And to do so we need rigorous, practical tools for health creation.

In countries such as Australia where naturopathy is thriving, healthcare systems now have a new and powerful tool in the quest for health creation. Sarris and Wardle further operationalise this effort in *Clinical Naturopathy* by providing a practical clinical handbook that includes succinct overviews of historical and modern naturopathic concepts such as its *principles of practice* and the *therapeutic order*, with a particularly strong emphasis on lifestyle, wellness and prevention strategies. We could indeed consider this work akin to a new *Merck Manual* for clinical health creation supported by current experimental evidence concerning traditional naturopathic concepts. *Clinical Naturopathy's* focus on functional systems, with an emphasis on determinants of health, gives clinicians a practical way to implement levels 1 and 2 of the therapeutic order—interventions that we believe are a vital component of health creation. Its coverage of naturopathic case taking and diagnostic perspectives successfully incorporates the vitalist worldview that strongly underpins naturopathic thinking and is essential to the clinical goal of increasing a patient's vitality and healing response. This text is a groundbreaking milestone in disseminating and communicating the rigorous principle-based application of naturopathy and will be extensively referenced in the forthcoming *Foundations of Naturopathic Medicine* textbook (in which Dr Wardle serves as an associate editor).

A universal issue I have observed in my legislative and policy work with the National Institutes of Health Center for Complementary and Alternative Medicine (NCCAM), the White House Commission on Complementary and Alternative Medicine (WHCCAM) and the Center for Medicare and Medicaid Services (CMS) Medicare Coverage Advisory Committee (MCAC) and other agencies, is the existing tension between the evidence for substance-based natural therapeutics versus the need for whole-practice research models that implement the health-creating potential in naturopathy and other integrative health disciplines. In the US today, a cacophony of voices, including (among many) the Integrative Healthcare Policy Consortium (IHPC), the Academic Consortium for Complementary and Alternative Healthcare (ACCAHC), the Academy of Integrative Health and Medicine (AIHM), the Institute of Medicine (IOM) and the Institute for Healthcare Improvement (IHI) under the leadership of Donald Berwick, MD,² have reiterated the call for health creation. Addressing the innovation required for healthcare practices and systems to attain this goal, Berwick acknowledges that 'the way to health may be vastly further from the current design of care than we may at first wish it to

be, or believe it to be ... The pursuit of health, the *creation of health*, may require something even bolder. The redesign we need may be even more radical than we have imagined'.² *Clinical Naturopathy* is a landmark step towards the innovation required for health creation and another link in the long chain of codification of naturopathic knowledge. This textbook will further enable today's clinicians to continue the timeless naturopathic approach of 'treating disease by restoring health'. With the launch of this second edition, Drs Sarris and Wardle hope *Clinical Naturopathy* contributes to 'shaping better healthcare'. As all of us steadily progress towards the call for health creation and changing the therapeutic order of global healthcare, I'm certain these distinguished authors and this book will have achieved their goal.

Pamela Snider, ND
Executive and Senior Editor
Foundations of Naturopathic Medicine Project
North Bend, Washington

- 1 Institute of Medicine 2013, *Shorter Lives, Poorer Health*. National Academy of Sciences, Washington, DC.
- 2 Institute for Healthcare Improvement 2013, Twenty-fifth National Forum keynote address, Donald M Berwick. Online. Available: <http://www.youtube.com/watch?v=r5Tbikk44jY10> Mar 2014. Donald Berwick is also the past Director, Center for Medicare and Medicaid Services, Health and Human Services.

Preface

The profession of naturopathy is steadily evolving. It was intended with the release of the first edition of *Clinical Naturopathy* that our text would play a role in that evolution. We have pleasingly received consistent positive feedback that the book has contributed to raising the standard of the profession towards a more evidence-based model. As discussed in the preface of the first edition, we do however recognise that the field should not sacrifice the core philosophical tenants that place it as a unique healing system in the pursuit of 'evidence-based medicine'. To that end, the creation of the second edition was focused on reconnecting more with the fundamentals of naturopathy, as well as pushing the scientific boundaries even further. As an example, this edition has a 'wellbeing' chapter that outlines the principles of naturopathic practice and provides a foundation for a prescriptive approach beyond the product-focused world of modern naturopathy. To balance this with a deepening scientific focus, we have an expanded diagnostics chapter with a new section on the emerging field of pharmacogenomics. We have also amended the appendices section, strengthening the elements where clinicians and educators requested more information, while removing parts that may be seen as tokenistic or better placed in more specialised texts (e.g. iridology and traditional Chinese medicine).

In respect to the changes for this second edition, we first wished to harmonise the chapters and provide a more cogent structure. By removing duplication and consolidating some material, we have been able to make room for an abundance of new material (including four new chapters and updated research and references). As patients rarely fit into textbook examples, and as individualisation of treatment is integral to naturopathic philosophy, we made the tough decision of omitting the case studies. This, too, was based on extensive feedback from practitioners who told us they wanted more information to critically apply to individual patients rather than prescriptive protocols that may or may not be relevant to their particular patients.

We respect that the practise of naturopathic medicine is complex and individualised, and thus acknowledge that this text does not provide a definitive 'how-to' guide. As with the first edition, the purpose of this text is to articulate evidence-based clinical practice (principles, treatment protocols and interventions) in a reader-friendly format for practitioners, academics and students. We wanted the book to be comprehensive enough as a robust desk reference to adequately provide the information necessary to inform most clinical scenarios, but compact enough to be carried between classes. It is a book we hope will be thumbed through extensively, rather than one that spends most of its life on a shelf.

A strength of this text that we have maintained, is that it explores the key principles and philosophies used in modern naturopathy for treating a range of conditions. The essence of this is detailed in the 'key treatment protocols' section in each chapter. An additional strength is the critical evaluation of the current evidence of both diagnostic and practice methods, and CAM interventions. This differentiates *Clinical Naturopathy: an evidence-based guide to practice* from some other publications that, while informative, often do not provide an evidence-based, referenced analysis of the treatment protocols underpinning the therapeutic use of CAM interventions.

To provide a balanced and truly academic discussion, the limitations of the book must be outlined. First, it is recognised that it is not possible to detail all diseases and disorders that are encountered in clinical practice. As any naturopathic clinician will know, *people* are treated, not *diseases*, and each person manifests a unique combination of variations of signs and symptoms rather than an isolated textbook diagnosed disease. Regardless, categorisation by major diseases and illnesses is a necessity to provide a framework with which to discuss naturopathic treatment protocols and interventions. The protocols and principles discussed in each chapter will in many cases be clinically relevant to the treatment of various other conditions where similar underlying causes exist. To assist readers we have facilitated some links between chapters, but we also acknowledge that there are far more than has been detailed.

With respect to the evidence reviewed, it should be noted that we focus primarily on the major evidence from clinical trials over that of *in vivo* or *in vitro* studies. Traditional evidence is also discussed when relevant. It will be apparent to readers that not every method, diagnostic technique or intervention included in this book has solid clinical evidence, and some herbal medicines or nutrients have only traditional evidence. It would be remiss to ignore those treatments and practices based on traditional evidence that form core parts of modern naturopathic practice in strict deference to modern scientific evidence. Regardless, research is undoubtedly the best way to uncover 'new knowledge' and test 'old knowledge'. One of the developments we hoped to see arise from the last edition was a further interest in conducting research that accurately reflects and tests naturopathic clinical practice. Research in the naturopathic medicine field, however, remains nascent, and more effort is required to foster research in the field.

We aimed to make this an easy-to-read clinical text; because of this some technical details such as the use of *p* values and effect sizes were omitted from the narrative and limited to the evidence tables. In light of this, the term 'significant' has been used when an intervention is revealed to have a *p* value of < 0.05 (likely to occur less than 5% due to chance). As this is meant to be a clinical reference, rather than a purely academic tome, detailed analysis of each and every trial was not entered into. However, all treatments have been duly referenced and readers, as always, are encouraged to explore these further. A selection of relevant further reading has been listed by individual contributors for those who wish to undertake additional investigation of the chapter content. A vocabulary alteration that can be noted in this edition is the use of the word 'nutraceutical' throughout the text. This is in place of the generic use of the term 'CAM', and is used to describe any nutrient or plant-based medicinal product.

The future direction of naturopathy and complementary medicine more broadly appears positive, with mainstream acceptance evolving in countries such as Australia, the United States, the United Kingdom, Germany, Canada and South Africa. To maintain the development of the profession and to enable more effective healers, education is paramount. *Clinical Naturopathy: an evidence-based guide to practice, 2nd edition* is developed to be at the forefront of naturopathic education in the 21st century. This book is designed for naturopaths, allied health or orthodox medical practitioners, researchers and anyone with an interest in principles, practices and treatments of natural medicine. We are immensely proud of this second edition and the fantastic contributions from the leaders in our field, and feel honoured that this may in part contribute to shaping better healthcare.

Jerome Sarris and Jon Wardle

CHAPTER 7

Liver dysfunction and disease

Ses Salmond
ND, BA, PhD

OVERVIEW

It is important to understand the functions of the liver, the systemic implications of liver disease and the importance of also treating the liver as an adjunct to other conditions, such as metabolic syndrome and hormone dysregulation.

The liver is involved in the metabolism of carbohydrates, proteins and fats. It converts simple carbohydrates in the form of fructose and galactose to glucose and then converts glucose to glycogen for storage. If carbohydrate intake exceeds requirements sugars are converted to triglycerides (TG), contributing to dyslipidaemia.¹


Protein metabolism in the liver is responsible for the synthesis of non-essential amino acids and functional proteins such as: fibrinogen and prothrombin for clotting; transferrins and lipoproteins for transport of iron and cholesterol, respectively; albumin for maintaining oncotic pressure; and globulins for immune function. Amino acids are also important for maintaining blood pH. If protein metabolism in the liver is disturbed this can lead to: bleeding disorders such as oesophageal varices and excess bruising; ascites due to low albumin and reduced oncotic pressure; impaired immune function; anaemia and fatigue as seen in non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) and hepatitis C virus (HCV) infection.

The liver is also involved in the production and regulation of triglycerides, phospholipids, lipoproteins and cholesterol. It metabolises fats by lipolysis and transforms fatty acids via β -oxidation to acetyl-CoA, the substrate for energy production via the Krebs cycle.¹ The liver stores fat-soluble vitamins (A, D, E, K) and other vitamins and minerals (B12, Zn, Fe, Cu, Mg). The liver converts carotene to vitamin A, folate to 5-methyl tetrahydrofolic acid and vitamin D to 25-hydroxycholecalciferol.

The liver synthesises bile, which emulsifies lipids and fat-soluble vitamins in the intestines to aid digestion and prevent cholesterol precipitation in the gallbladder. Bile synthesis and excretion is also a mechanism for reducing excess cholesterol. Another major role of the liver is the metabolism and detoxification of: alcohol; synthetic and natural drugs; steroidal hormones such as the corticosteroids, testosterone, progesterone and oestrogen; non-steroidal hormones such as thyroid hormones; and insulin and growth hormones. It also converts ammonia to urea.¹

Common pathways of liver disease

Liver diseases can have a variety of causes but can progress through similar pathology, therefore different aetiologies of liver disease can have common treatments, as shown in Figure 7.1.



HCV = hepatitis C virus; NFLD = non-alcoholic liver disease;
NASH = non-alcoholic steatohepatitis; ALD = alcoholic liver disease

Figure 7.1

Common pathology and treatment in liver diseases

Aetiologies

- Viral infection—hepatitis (A, B, C, D, E)
- NAFLD/non-alcoholic steatohepatitis (NASH), dysregulated free fatty acid (FFA) metabolism and accumulation due to obesity, insulin resistance and metabolic syndrome
- ALD, accumulation of toxins due to excess alcohol consumption

Common pathology

- *Hepatitis (B and C)*. Increased oxidative stress as a direct consequence of the virus and indirectly as a result of the immune response.
- *NAFLD and NASH*. Increased oxidative stress as a result of FFA accumulation and lipid peroxidation, exacerbated by increased inflammatory cytokines from adipose tissue, damages the liver.
- *ALD*. Increased oxidative stress as a result of toxins.

Common treatment—reduction of hepatic inflammation

Oxidative stress in liver disease accelerates inflammation, fibrosis and necrosis, creating additional oxidative stress, which causes further damage to proteins, DNA, lipids and sensitises redox-regulated necrotic cell signalling pathways, affecting gene expression² and

causing mitochondrial dysfunction and pathology.³ Increased oxidative stress leads to reduced liver function and can progress through fibrosis to cirrhosis and possibly cancer.

Liver disease can lead to metabolic syndrome with dysglycaemia or dyslipidaemia and increases in the frequency of comorbidities.⁴

Treatment based on reducing oxidative stress, inflammation, regulating digestive dysfunction and supporting fatigue will assist in the treatment of most chronic liver diseases.

Common comorbidities

- Metabolic syndrome
- Cardiovascular disease
- Depression and fatigue
- Hormonal dysregulation
- Dyspepsia

NON-ALCOHOLIC FATTY LIVER DISEASE

NAFLD is the hepatic manifestation of metabolic syndrome.⁵⁻⁷ The Asia-Pacific Guidelines on NAFLD recommend that the term NAFLD is retained for cases of fatty liver associated with the metabolic complications of over-nutrition, usually with central obesity and overweight.⁸ NAFLD is the most common liver disease worldwide in adults and children.⁹ NAFLD usually occurs in the fourth or fifth decade of life and is predominantly asymptomatic. NAFLD may progress from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. An estimated 20–35% of the general population has steatosis, 10% developing more progressive NASH, which is associated with increased risk of cardiovascular and liver-related mortality.¹⁰

The prevalence of NAFLD is higher among the obese and patients with type 2 diabetes. In fact in a cohort of NAFLD patients, 50% had diabetes, 44% had hypertension and 12% had previous vascular disease.¹¹ The environmental factors involved in NAFLD and metabolic syndrome are diet, physical activity and gut microflora. Metabolic syndrome with dysglycaemia, dyslipidaemia and obesity results in an increase in the level of FFAs from the breakdown of adipose tissue and from the metabolism of excess dietary carbohydrates (hyperlipidaemia); this dysregulation leads to lipotoxicity in the liver, causing oxidative stress and liver inflammation.¹⁰

Signs and symptoms

- Fatigue⁷ and depression¹³
- Right upper quadrant pain or discomfort or fullness, possibly due to stretching of the hepatic capsule and hepatomegaly⁹
- Metabolic syndrome⁷—type 2 diabetes mellitus, insulin resistance (IR), hyperlipidaemia and obesity
- Acanthosis nigricans,⁹ a cutaneous manifestation of IR, was found in 12% of NAFLD patients. This regional hyperpigmentation is typically found in adults around the neck, over knuckles, elbows and knees and offers the clinician and patients a physical clue as to the presence of IR.¹²

Pathophysiology

The hallmark of NAFLD is the deposition of excess FFAs within hepatocytes and is associated with the loss of insulin sensitivity.¹⁴ There are theories as to whether the fat

accumulation in the hepatocytes occurs first or IR; the literature is moving towards the theory that IR occurs first.^{7,10}

Hepatic FFAs' concentration is increased by the following:^{15,16}

- Obesity and IR cause excess FFAs in the liver from adipose tissue—60%.
- IR increases *de novo* lipogenesis (DNL) from excess dietary carbohydrates—25%.
- Poor diet increases dietary fatty acids—15%.
- Lipotoxicity, oxidative stress and mitochondrial damage results in decreased hepatic β -oxidation of FFAs.¹⁷
- Steatosis reduces very low density lipoprotein (VLDL) synthesis, export and clearance of FFAs.

Excess FFAs accumulate in the liver, leading to macrovesicular steatosis and lipid-induced cellular injury, worsening hepatic IR and reducing hepatic function; this contributes to a vicious cycle.^{7,10} Both IR and obesity are pro-inflammatory conditions, resulting in high oxidative stress exacerbated by the aldehyde by-products of lipid peroxidation, which increase the production of pro-inflammatory cytokines and recruit inflammatory cells into the liver.¹⁰

In summary, the pathophysiology of NAFLD is complex and includes IR, disrupted lipid, protein and carbohydrate homeostasis, oxidative stress, FFA-mediated lipotoxicity, defects in mitochondrial function, endoplasmic reticulum stress, cytokine mediated toxicity, inflammation and fibrosis.¹⁷

Diagnosis

A diagnosis of NAFLD requires confirmation of hepatic steatosis, with the additional exclusion of excessive intake of alcohol. The alternative causes for fatty liver (genetic, viral, metabolic, drug) must be excluded before a diagnosis of NAFLD can be made.¹⁰

Clinically, elevated liver transaminases, gamma glutamyl-transpeptidase (GGT), hypertriglyceridaemia, ferritin⁹ and numerous weight-loss and weight-gain cycles would alert the practitioner to a possible NAFLD diagnosis. Serum ferritin is elevated in 20–50% of NAFLD patients and the raised transferrin saturation (> 55%) occurs in 5–10% of patients; both may reflect hepatic steatosis and fibrosis due to oxidative stress and inflammation. Hypertriglyceridaemia is often present in more than 50% of NAFLD patients.⁹ Refer to Appendix 5 for more information on laboratory reference values.

An ultrasound of the liver, computer tomography and magnetic resonance imaging will detect moderate to severe steatosis (> 30% steatosis). A liver biopsy may be necessary to quantify the degree and stage of hepatic steatosis and fibrosis. The presence of more than 5% of steatotic hepatocytes in a section of liver tissue from a liver biopsy is the accepted minimum standard for a histological diagnosis of NAFLD.¹⁸

DIFFERENTIAL DIAGNOSIS—NAFLD

- Non-alcoholic steatosis
- ALD⁷
- HCV
- Wilson's disease⁷
- Cardiovascular disease
- Gallbladder disease
- Irritable bowel syndrome

Risk factors

Practitioners should be aware of the existence of conditions that commonly co-occur with NAFLD. The presence of NAFLD is an independent risk factor for coronary artery disease.¹⁹ The hepatic metabolism of methionine is perturbed in NASH,²⁰ which may provide a reason for the increased coronary artery risk in this population. Recently polycystic ovarian syndrome was proposed as the ovarian manifestation of metabolic syndrome.²¹

Risk factors for mortality in NAFLD patients are the presence of cirrhosis, impaired fasting glycaemia or diabetes.²²

NAFLD: at-risk groups

- Histological NASH on diagnosis²²
- Metabolic syndrome^{4,5}
- Major health conditions (especially cardiovascular disease)^{19,20}
- Older age²²
- Smokers²³

Conventional treatment

Although there is no pharmacological agent approved for treating NAFLD, vitamin E (in patients without type 2 diabetes mellitus) and thiazolidinedione pioglitazone (in patients with and without type 2 diabetes mellitus) have shown the most consistent results in randomised controlled trials.²⁴ However, a recent systematic review of the use of thiazolidinediones (peroxisome proliferator activator receptor- γ agonists) in NAFLD concluded that while they modestly improve fibrosis and hepatocellular ballooning, it is at the cost of significant weight gain. In seven randomised trials the average weight gain was 4.4 kg (CI, 2.6–5.2 kg).²⁵ There is an increased cardiovascular risk with rosiglitazone. Other side effects are fluid retention and osteoporosis. The evidence that insulin-sensitising drugs are able to modify the natural history of NAFLD is not currently available.²⁶

Key treatment protocols

The first goal is to address the metabolic syndrome picture and reverse the lipotoxicity and insulin resistance via lifestyle interventions²⁴ using diet and exercise.

At the same time it is important to protect the liver from oxidative stress and subsequent inflammation and fibrosis, as well as supporting liver function and healing. Supporting the digestive system will reduce the dyspeptic symptoms of NAFLD thereby improving client wellbeing and nutrient status. Two of the major symptoms of NAFLD are fatigue and depression so in order to motivate the client to make positive lifestyle choices the treatment protocol needs to address these issues.

Naturopathic Treatment Aims

- Encourage beneficial dietary and lifestyle changes.
- Treat the underlying metabolic causes:
 - modulate fatty acid pathways
 - regulate blood glucose
 - reduce weight.
- Reduce hepatic inflammation:
 - reduce oxidative stress.
- Reduce inflammation.
- Reduce the likelihood of fibrosis.
- Support liver function.
- Support digestive function.
- Support mood and energy levels.

Encourage beneficial dietary and lifestyle changes

Dietary and lifestyle advice

Identifying and removing potential liver stresses is one of the first steps in instigating beneficial lifestyle changes, such as alcohol moderation and smoking cessation. The diet needs to be low in carbohydrates and particularly low in high-fructose corn syrup as fructose is lipogenic and stimulates triglyceride synthesis.²⁷ Where there is a high-fructose diet, especially with soft drink consumption, all the signs relating to NAFLD are present: increased blood glucose, triglyceride, alanine aminotransferase (ALT), cholesterol, weight and hepatic steatosis. In NASH patients high fructose ingestion was associated with hepatic insulin resistance and higher fibrosis.²⁸ High-fructose diets increase hepatic reactive oxygen species (ROS) and macrophage aggregation, resulting in TGF-beta-1 signalled collagen deposition and hepatic fibrosis.²⁹ This potentially leads to decreased copper absorption and a resulting deficiency.^{30,28}

The diet should also be high in protein, fibre, good fats, antioxidants and anti-inflammatory foods such as lean meat and fresh vegetables to regulate blood glucose levels and support antioxidant status, bowel and liver function. High-protein diets prevent and reverse steatosis independently of fat and carbohydrate intake more efficiently than a 20% reduction in energy intake.³¹ The effect appears to result from small, synergistic increases in lipid and branched-chain amino acids (BCAA) catabolism, and a decrease in cell stress. Similarly, low-carbohydrate diets are useful in reducing circulating insulin levels and decreased intrahepatic triglycerides (IHTG) due to enhanced lipolysis and fatty acid oxidation.³² Studies involving low-carbohydrate diets with less than 50 g/day of carbohydrate saw a reduction in insulin sensitivity and decreased endogenous glucose production rate—more than an isocaloric low-fat diet—and encouraged hepatic and visceral fat loss. Attention to nutrition status is important as malnutrition accounts for more than 60% of patients with severe liver failure and negatively affects clinical outcomes in terms of survival and complications.³³

Exercise or physical activity

Exercise of sufficient duration and intensity will reduce adipose tissue therefore reducing a source of adipose-derived FFAs; it also enhances insulin sensitivity. Exercise will increase muscle mass, adiponectin and the biogenesis of mitochondria. **Endurance exercise** uses muscles that use triglycerides for energy rather than carbohydrates and therefore there is an overall decrease of FFAs and an increase in the β -oxidation of FFAs in NAFLD.^{16,26,34,35}

There is emerging and growing evidence for the effectiveness of increasing physical activity reducing hepatic fat content,²⁶ regardless of whether it is resistance based or aerobic or combined with diet and weight loss. Therefore it is important to find some form of exercise that is physically possible for the patient. **Resistance exercise** independent of weight loss is also associated with significant reduction in hepatic fat³⁵ and may improve insulin sensitivity more than aerobic exercise alone.³⁴ Resistance exercise may be more accessible to some patients than aerobic exercise and may achieve better compliance than diet, therefore it is a more sustainable treatment option.³⁵

Aerobic exercise training and dietary restriction can positively affect NAFLD when weight loss approximating 4–9% of body weight is achieved; an inverse correlation between NAFLD and physical activity or fitness levels has also been demonstrated.^{16,26,34} Weight loss, irrespective of diet, reduces aminotransferases in obese women with NAFLD³⁶ and 7–10% weight loss coincided with significant histological improvement

of liver disease.³⁷ Therefore a combination of exercise, diet and weight loss is synergistic in the amelioration of liver disease in NAFLD.

A systematic review with meta-analysis concluded that exercise is efficacious in modifying liver fat in adults. Interventions ranged from two to 24 weeks in duration and prescribed exercise on two to six days per week at intensities between 45% and 85% of VO_{2peak} .²⁶ The review could not report an improvement in ALT due to many ALT measures being normal at baseline and because studies with positive results were excluded due to lack of a control group. In a study that lacked a control group a near 50% reduction in ALT was achieved in patients who complied with the prescribed exercise regimen, indicating reduced liver inflammation.³⁸ The exercise regimen consisted of aerobic exercise for 30 minutes per day at a heart rate of 60–70% of maximal for at least five days a week for three months.

In rodents regular exercise reduced DNL, increased β -oxidation and increased the removal and clearance of FFAs via VLDL. Sedentary behaviour, on the other hand, resulted in the reduced oxidation of fatty acids and mitochondrial activity with the up-regulation of fatty acid synthesis.^{16,26}

Kistler et al. suggest that intensity of exercise may be more important than duration or total volume of exercise in the treatment of NAFLD, with vigorous activity associated with significantly lower odds of fibrosis.³⁹ The suggested mechanisms for the benefits of vigorous exercise over moderate are that vigorous exercise increases adiponectin and AMP-activated protein kinase (AMP-kinase) in the liver, which increases fatty acid oxidation, decreases glucose production, regulates mitochondrial biogenesis and reduces inflammation and fibrosis.^{39,40} Decrease in adiponectin plays a significant role in metabolic disorders such as obesity, type 2 diabetes, coronary heart disease and metabolic syndrome due to its insulin sensitising, anti-inflammatory and anti-atherogenic properties.⁴¹ Decreases in adiponectin and increases in leptin in metabolic syndrome and obesity are linked to fibrosis in NAFLD.⁴² Coker et al.⁴³ found that exercise training with calorie restriction achieved better results in visceral fat loss, weight loss and improvements in insulin resistance than calorie restriction alone.

Treat the underlying metabolic causes

Modulate fatty acid pathways and regulate blood glucose

In obese individuals it is important to reduce adipose tissue as a source of FFAs as well as to control insulin resistance that results in excess lipolysis of adipose tissue. Also, controlling insulin resistance will help decrease rates of DNL from carbohydrate metabolism. Exercise can reduce adipose tissue and improvements in insulin resistance combined with a diet containing low carbohydrates and healthy fats are essential to improving NAFLD. Strong evidence exists for **omega-3 fatty acids**⁴⁴ reducing hepatic fat content in children with NAFLD. **Vitamin E (natural)**⁴⁵ as a fat-soluble antioxidant is also useful in reducing lipid peroxidation in NAFLD.

Whole *Curcuma longa* oleoresin up-regulated the expression of genes related to glycolysis, β -oxidation and cholesterol metabolism in obese diabetic KKAY mice and down-regulated the gluconeogenesis related genes (see Chapter 19 on diabetes for more information).⁴⁶

Reduce hepatic inflammation

The inflammatory process causes oxidative stress and vice versa, driving liver disease progression. Therefore a key treatment goal in NAFLD is to reduce hepatic inflammation

and oxidative stress by using hepatoprotective herbal medicines with specific hepatic anti-inflammatory and antioxidant activity. Hepatoprotection is defined as more than just antioxidant and anti-inflammatory effects; it also includes several non-mutually exclusive biological activities including antifibrotic, antiviral and immunomodulatory functions.⁴⁷

One of the ways that oxidative stress damage can be reduced is through hormesis. It is postulated that hormesis is a mechanism by which phytochemical adaptogens such as *Astragalus membranaceus* and antioxidant-rich plants such as *Silybum marianum* strengthen mitochondria by improving the β -oxidation of FFAs, increasing energy and stamina.⁴⁸ In calorie restriction, exercise and hormesis, increased ROS up-regulates adaptive responses. This results in a net reduction in ROS due to the stimulation of antioxidant defences and detoxification.⁴⁹ This adaptation or preconditioning of the mitochondria has been named 'mitochondrial hormesis' or 'mitohormesis'.^{50,49,51} These hormetic pathways, activated by phytochemicals, include the sirtuin-FOXO pathway, the NF-kappa B pathway and the Nrf-2/ARE pathway.⁴⁸ Surh⁵² terms this exogenous form of hormesis 'xenohormesis'.^{48,53} Bitter foods such as dandelion coffee, rocket and radicchio also have a hormetic effect as well as stimulate digestion and aid dyspepsia.

Silymarin (an active constituent of *Silybum marianum*) protects cells against oxidative stress by stabilising cell membranes, radical scavenging, chelating iron and supporting endogenous antioxidants such as glutathione.⁵⁴ *Silybum marianum* also has anti-inflammatory^{55,56} and antifibrotic^{57,58} effects through the reduction of inflammatory cytokines and TNF- α as well as hypoglycaemic, choleric and cholagogic actions. The latter two actions help remove fat from the liver through the fatty acid metabolism pathways, thereby preventing deposition of fat in the liver.

Curcuma longa interrupts insulin signalling, which stimulates hepatic stellate cell activation (a key element in fibrogenesis), suppresses the gene expression of type I collagen and also increases the *de novo* synthesis of glutathione, thereby exerting anti-inflammatory, antioxidant, antidiabetic and antifibrotic effects.⁵⁹ The antioxidant and anti-inflammatory actions of **baicalin** and *Scutellaria baicalensis* make it a very useful clinical tool in NAFLD⁶⁰ and ALD⁶¹ management.

Baicalin, the active ingredient in *Scutellaria baicalensis*, has been shown to reduce dyslipidaemia and hepatic lipid accumulation, improve hepatic steatosis and reduce visceral fat mass in vivo.⁶⁰

Glycyrrhiza glabra has an anti-inflammatory effect in NAFLD by lowering elevated ALT and aspartate aminotransferase (AST) in a randomised, double-blind, placebo-controlled clinical trial.⁶² The biologically-active metabolite of **glycyrrhizin** (18 beta-glycyrrhetic acid (GA)) prevented FFA-induced lipid accumulation and toxicity by stabilising the lysosomal membranes, inhibiting cathepsin B activity and inhibiting mitochondrial cytochrome *c* release.⁶³ Another preparation of GA (**carbenoxolone**, 3-hemisuccinate of glycyrrhetic acid) inhibited pro-inflammatory cytokine expression, inhibited FFA-induced ROS formation and reversed FFA-induced mitochondrial membrane depolarisation in HepG2 cells. GA also prevented the development of fatty liver by inhibiting the sterol regulatory element binding protein 1c (SREBP-1c) expression and activity via antiapoptotic mechanisms and the inhibition of inflammatory cytokines and ROS formation in the liver.⁶⁴

Grapeseed extract improved markers of inflammation and glycaemia in obese type 2 diabetes mellitus patients⁶⁵ and reduced ALT and improved grade of steatosis in NAFLD patients.⁶⁶ (See Chapter 19 on diabetes and Chapters 11–13 on the cardiovascular system for more information.)

Both **omega-3**⁴⁴ and **vitamin E (natural)**⁴⁵ have shown some effectiveness in reducing inflammation in NAFLD and/or NASH. Deficiencies in vitamin E lead to an increased risk of developing advanced inflammation (6.5 fold) and lower riboflavin intake is associated with increased risk of advanced steatosis (6.2 fold) compared with those chronic hepatitis C patients with adequate intakes.⁶⁷

Accumulation of lipids in the hepatocyte impairs the metabolic capacity of the mitochondria, leading to a buildup of reduced electron transport chain substrates and lipid peroxidation, leading to increased ROS.⁶⁸ Therefore stimulation of mitochondrial function through **L-carnitine**,^{69,70} **alpha lipoic acid**⁷¹ and **coenzyme Q10**⁷² may be effective in NAFLD and other liver conditions associated with mitochondrial dysfunction. **Melatonin** (5 mg) and **tryptophan** (500 mg) twice daily for four weeks reduced the plasma levels of pro-inflammatory cytokines in NASH.⁷³

Support liver function

Herbs that support liver function such as *Silybum marianum*, *Berberis aristata*,⁷⁴ *Cynara scolymus*,⁷⁵ *Curcuma longa*⁴⁶ and *Schisandra chinensis* also help support the production and elimination of bile that promotes the elimination of cholesterol, which lowers FFAs (see Table 7.1 and Figure 7.2).⁷⁶ See the liver detoxification section below for herbs and nutrients specific to support detoxification. **SAMe**⁷⁷ supports methylation and has shown some effectiveness in NAFLD and NASH. **N-acetylcysteine** (600 mg/day) reduced ALT in NAFLD patients and improved liver function through supporting glutathione production.⁷⁸

Reduced dietary protein intake is an independent predictor of complications in cirrhosis.^{79,80} In those with liver cirrhosis with low serum albumin or globulin, extra **protein**, approximately 1.0–1.2 g of protein per kilogram of body weight,⁸¹ is required to assist the liver to synthesise proteins. Compromised liver function will also result in reduced protein synthesis, possibly resulting in signs such as prolonged prothrombin time due to reduced synthesis of clotting factors. The provision of a night-time feed to cirrhotic patients led to a body protein increment of about 2 kg of lean tissue sustained over 12 months.⁸²

Support liver detoxification

A protocol to enhance liver detoxification is an adjunct treatment to all acute and chronic inflammatory conditions and conditions associated with hormone imbalance through the removal of exogenous and endogenous toxins that may cause oxidative stress, drive inflammation and act as carcinogens.

Liver detoxification refers to the phase I, phase II and phase III enzymes in the liver. Phase I enzymes activate both toxins and drugs, potentially increasing the effects of both. Phase II enzymes conjugate the metabolites of phase I, making them more water soluble and available for excretion, thereby reducing toxic metabolites and the need for therapeutic drugs.⁸³ Phase III involves the mobilisation of the products of phase II from the intracellular environment to the extracellular environment for excretion as bile, urine, sweat and via the lungs. Toxic compounds such as 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD), polycyclic aromatics and beta-naphthoflavone induce both phase I and phase II activity.⁸⁴ Conversely, therapeutic interventions tend to inhibit phase I and induce phase II, protecting the body from a buildup of the toxic metabolites of phase I (Table 7.1 and Figure 7.2).

A detoxification protocol requires, first of all, a healthy diet and good digestive function to reduce the intake and maximise the output of toxins. This should be combined with lifestyle changes such as exercise and relaxation and be supported by foods, nutrients




Figure 7.2
Biochemical and nutritional factors affecting liver metabolism

Foods containing **flavonoids** (e.g. kaempferol, diosmetin, theaflavin and biochanin A) can inhibit the metabolic activation of procarcinogens by phase I enzymes and some dietary flavonoids (e.g. naringenin, quercetin, biochanin A and prenylchalcones) can stimulate the detoxification of carcinogens by inducing phase II enzymes.⁸⁷ A review cautions that a number of studies have demonstrated inhibition and induction effects on drug bioavailability by flavonoids, raising concerns about the safe use of flavonoid supplements that are not subject to legal regulations.⁹⁰ *Allium sativum* can be beneficial through an inhibitory effect on phase I¹¹¹ and an induction effect on phase II⁹⁶ enzymes

as well as increasing the synthesis of endogenous antioxidants and glutathione via Nrf2/ARE⁹⁷ and is therefore very useful in detoxification and easily accessible as a food. Another food example is the phytochemical phenethyl isothiocyanate, a constituent of **cruciferous vegetables** that can modulate cytochrome P450 composition in human liver at concentrations that can be achieved by dietary intake.⁹⁵ This can antagonise the carcinogenicity of chemicals that rely on the CYP1 family for their bioactivation such as heterocyclic amines and polycyclic aromatic hydrocarbons.⁹⁵

Teas can be used to hydrate and to gently cleanse the body, with various herbal teas and dandelion root coffee potential choices. Also the use of **culinary herbs and spices** such as turmeric, cumin, fenugreek, rosemary and sage is a great way to introduce a variety of herbs into the diet. Diets low in **protein** may predispose patients to lowered liver detoxification, as key amino acids are involved in these liver processes.^{31,81} Increasing crude protein intake will also help to improve availability of amino acid precursors for conjugation.

Fasting is also known to enhance the detoxification process,¹¹² in part because the main source of energy is hydrolysed fatty acid tissue from adipose tissue stores, where many toxins are stored.¹¹³ However, due prudence needs to be displayed, as fasting may liberate toxins faster than they can be eliminated (because in part the adequate substrates from phase II detoxification may be missing or compromised) and may potentially endanger the patient.

Hydrotherapy is thought to increase filtration through the liver by encouraging blood circulation, in addition to aiding excretion through sweating.¹¹³ Sauna therapy has also been used to encourage elimination through the skin, with substantial elimination and significant clinical improvement thought possible through this mechanism.^{112,114} **Sauna** exposure of five to 15 minutes per day is safe and effective in enhancing detoxification, though caution is advised in patients with recent myocardial infarction or other serious cardiovascular complications, and patients need to be advised that eliminating toxins through the skin may initially irritate (though ultimately improve) conditions such as atopic dermatitis.¹¹⁶ Many nutrients, particularly trace elements such as zinc, copper, iron and chromium as well as electrolytes, may be lost through sweating and may need monitoring or replacement.

Some herbs have a history of use for detoxification and are used in traditional herbal medicine for their role in supporting liver function including *Silybum marianum*, *Cynara scolymus*, *Bupleurum falcatum*, *Schisandra chinensis*, *Peumus boldo* and *Taraxacum officinale*. Herbs such as *Silybum marianum* and *Schisandra chinensis* can increase levels of Nrf2 either by stimulating its release or inhibiting its proteolytic breakdown. Activated Nrf2 translocates into the nucleus where it interacts with small MAF family proteins bound to the antioxidant response element (ARE), allowing transcription of target genes including those that regulate antioxidant and phase II enzymes.¹⁰⁶

Exercise will also promote hepatic biotransformation processes.^{117,118}

Detoxification is also an area in which unproven and often ineffective remedies are aggressively marketed, both to practitioners and to patients, implying careful consideration before their use in clinical practice.¹¹⁹ Therefore, while detoxification regimens may provide a clinically valuable adjuvant to treatment, naturopathic practitioners should be sure to focus on more relevant primary treatment aims in the clinical setting. More extreme detoxification methods can be very dangerous and should be avoided. While it is true that many traditional methods may fall into this category, it should also be acknowledged that these traditions were born of a time when environmental toxic burdens were far lower and would have resulted in fewer side effects and lower risk.

Support digestive function

Dyspeptic symptoms associated with NAFLD include burping, bloating, reflux, flatulence and indigestion with intolerances to fatty foods. Common herbal medicines used to stimulate secretion of bile and pancreatic enzymes are *Gentiana lutea* and *Cynara scolymus*. Bitter foods such as dandelion coffee, rocket, radicchio, watercress, radish, cauliflower and the rest of the Brassicaceae family also stimulate digestion. Cholagogues aid digestion and carminatives reduce spasm and wind. Dysbiosis plays a role in the pathogenesis of liver disease through inflammation and damage to the epithelial cells of the intestines. This damage can then expose the liver to intestinally derived toxins such as ethanol and lipopolysaccharides (LPS), which drive inflammation in the liver.¹¹⁰

Probiotics, prebiotics and increased dietary fibre can be used to help restore intestinal flora balance and function to the gastrointestinal tract. They can be useful in reducing the enterohepatic reabsorption of toxins from the gastrointestinal tract. The inclusion of a range of probiotics such as *Lactobacillus bulgaricus* and *Streptococcus thermophilus* reduce hepatic necroinflammation in NAFLD patients.¹²⁰ *Bifidobacterium longum* with FOS and lifestyle modification significantly reduced tumour necrosis factor alpha (TNF- α), C-reactive protein (CRP), serum AST levels, HOMA-IR, serum endotoxin, steatosis and NASH activity score¹²¹ (see Chapters 4–6 on the gastrointestinal system for more detail).

Support mood and energy levels

A number of epidemiological studies have found links between chronic liver diseases such as NAFLD and hepatitis B and C with depression.^{122,123} Weinstein et al. suggest that NAFLD and HCV patients have a higher prevalence of depression than the wider population.¹³ Depression and mood disorders are often seen in obesity and diabetes mellitus, two of the major metabolic pictures seen in NAFLD. While mood disorders are not always present, they are relevant to some sufferers of chronic liver disease and symptoms must be supported. (See also Chapter 15 on depression and Chapter 18 on stress and fatigue.)

Integrative medical considerations

After a thorough naturopathic consultation, it may become apparent that the patient has a number of risk factors and symptoms that suggest the presence of NAFLD. If this diagnosis is not confirmed at the time of their initial consultation, a referral to a general practitioner in the first instance would be worthwhile for further investigation.

Refer for liver ultrasound or further medical care if there are signs of:

- severe fluctuations in weight (loss and gain)
- elevated GGT
- elevated ALT
- raised triglycerides
- raised ferritin.

Clinical summary

Refer to the naturopathic treatment decision tree (Figure 7.3) regarding clinical decisions in the treatment and management of liver disease. From the thorough case history taking and observation of the clinical signs and symptoms of liver disease, a potential diagnosis of NAFLD may be apparent. It would be useful to confirm the diagnosis of NAFLD with a general practitioner, who may refer the patient for biochemical tests and

liver ultrasound or liver biopsy if indicated. An individualised treatment plan considering causation, age, sex, culture, current dietary and lifestyle factors and family and social history should be discussed with the patient. This treatment plan would address the underlying causes (alcohol, viral infection, metabolic syndrome), support liver and digestive function, reduce inflammation and oxidative stress, address obstacles to healing and encourage beneficial dietary and lifestyle changes.




Figure 7.3
Naturopathic treatment decision tree—liver disease

OTHER LIVER AND BILIARY DISEASES

Hepatitis

Hepatitis, in particular chronic hepatitis C, affects 170 million people worldwide and approximately 2% of the adult Australian population. Chronic hepatitis C can lead to hepatic fibrosis, cirrhosis and hepatocellular carcinoma. It is the leading cause of liver transplantation in Australia.¹²⁴ Estimates indicate that 25 per cent of those infected with hepatitis C will clear the virus, with 75 per cent having chronic infection.¹²⁵ Clinical symptoms of chronic hepatitis C include fatigue,¹²⁶ right upper quadrant pain or discomfort, nausea, malaise, anorexia, pruritus, weight loss, arthralgia, musculoskeletal pain, night sweats and dry eyes (sicca syndrome). Extrahepatic manifestations of chronic hepatitis C are: mixed cryoglobulinaemia, glomerulonephritis, porphyria cutanea tarda, low-grade malignant lymphoma, autoimmune thyroiditis, Sjögren's syndrome, lichen planus, aplastic anaemia, polyarteritis nodosa, erythema nodosum, idiopathic pulmonary fibrosis and diabetes mellitus.¹²⁷ The pathophysiology of chronic hepatitis C is multifactorial and the key players are the hepatitis C virus directly, the immune response to HCV infection and oxidative stress.

DIFFERENTIAL DIAGNOSIS

- Chronic fatigue syndrome
- Fibromyalgia
- NAFLD
- NASH
- Autoimmune hepatitis

Risk factors¹²⁸

Modifiable risk factors include:

- intravenous drug and tobacco use
- blood transfusions
- tattoos
- needle-stick injuries
- steatosis
- insulin resistance, type 2 diabetes
- body mass index (BMI) over 25.

Non-modifiable risk factors include:

- age at acquisition of HCV infection
- age and necrosis stage at liver biopsy
- gender (male)
- duration of infection
- ALT levels ranging from 1.5–5 times the upper limit of normal (ULN), ALT > 70 IU/L and genetics (immune function and interferon sensitivity).

Conventional treatment

- Standard of care—pegylated interferon and ribavirin.¹²⁹ Treatment with pegylated interferon and ribavirin leads to a sustained virological response (SVR) in 84% of hepatitis C patients with genotypes 2 and 3 (24 weeks) and 52% in genotype 1

(48 weeks).¹²⁹ The numbers treated with antiviral therapy in Australia through the highly specialised (S100) program in 2010 was 3760¹³⁰

- Additional medications—protease inhibitors telaprevir¹³¹ and boceprevir¹³²
- In development—interferon-free treatments^{133–135}

Key treatment protocols

- From a naturopathic clinical perspective, the goal of supporting treatment of chronic hepatitis C is to reduce oxidative stress caused by the hepatitis C virus (proteins) and the inflammatory mediators produced by the ineffectual immune response to the virus and thereby reduce disease progression in the form of inflammation, fibrosis, cirrhosis and potentially cancer.
- Encourage beneficial dietary and lifestyle changes. (See the NAFLD section above and Chapter 3 on wellness.)
- Antiviral and immune support. An immediate, strong and persistent CD4+ T-cell response^{136,137} and a vigorous multispecific cytotoxic T lymphocyte response^{137–140} against multiple HCV epitopes coupled with a predominant T helper 1 cytokine profile is more likely to encourage viral clearance in response to acute HCV infection.¹⁴¹ Herbal medicines such as *Astragalus membranaceus*,¹⁴² *Echinacea spp.*¹⁴³ and *Phyllanthus amarus*¹⁴⁴ which influence the Th1–Th2 balance may assist in both acute and chronic hepatitis C infection. **Zinc** and **vitamin E** are particularly important for an effective immune response. **Intravenous silibinin** has shown direct anti-HCV activity in chronic hepatitis C patients who were previous non-responders to standard therapy¹⁴⁵ and to prevent HCV re-infection after liver transplantation.¹⁴⁶
- The treatment strategies to reduce hepatic inflammation and oxidative stress, support liver function and digestive function and alleviate depression and fatigue are outlined in the NAFLD treatment protocol section.
- Use of specific nutraceuticals. Studies have shown that 2 g **L-carnitine** taken concurrently with interferon and ribavirin for 12 months helped chronic hepatitis C patients clear the hepatitis C virus and reduced fatty liver and fibrosis by 70%.¹⁴⁷ The sustained virological response was also greater in the L-carnitine group (46%) compared with the interferon and ribavirin group (39%). A total 800 IU **vitamin D3** per day given at the same time as pegylated interferon and ribavirin helped liver transplant patients with chronic hepatitis C achieve greater rates of SVR.¹⁴⁸ Between 50% and 73% of chronic hepatitis C patients were deficient in vitamin D3.^{149,150} Correcting vitamin D deficiency before antiviral therapy is recommended¹⁴⁸ as low vitamin D is linked to severe liver fibrosis and low levels of SVR on interferon-based therapy.¹⁵⁰

Cholecystitis

Cholelithiasis is the medical term for the presence of gallstones in the gallbladder. An estimated 14–20% of Australians will develop gallstones in their lifetime. There are three main types of gallstones: cholesterol stones—70% cholesterol crystals; black pigment stones—calcium bilirubinate present in haemolytic disorders; and brown pigment stones—linked to bacterial or helminthic infection in the biliary tree.¹⁵¹

In respect to aetiology and pathophysiology, hypersecretion of cholesterol and the hyposecretion of bile acids and phosphatidylcholine (lecithin)^{152,153} causes the bile to contain more cholesterol than the bile salts and phospholipids can solubilise. Chemical components of bile precipitate in the gallbladder and occasionally in the bile duct¹⁵¹ to form microscopic cholesterol-rich vesicles.¹⁵³ Pathogenic development of these

cholesterol-rich vesicles into macroscopic gallstones has been linked to hypomotility and excess biliary mucin excretion,¹⁵⁴ which is linked to hepatic cholesterol hypersecretion and a cycle of lithogenesis. Gallstones are asymptomatic in 60–80% of cases and, of those, only 10–20% will develop symptoms. Gallstone-associated pain can increase the risk of complications such as acute cholecystitis, cholangitis and pancreatitis.

Cholecystitis can be classified as acute or chronic. Acute cholecystitis is indicated if the pain lasts longer than 12 hours, and may be due to gallstone impaction in the cystic duct. The clinical presentations include fever, upper abdominal pain with marked tenderness and guarding in the right upper quadrant, especially with pain on palpation combined with inspiration, known as Murphy's sign due to elevated pressure within the gallbladder due to obstruction.¹⁵⁵ Chronic cholecystitis (or cholelithiasis) is the most common clinical presentation of symptomatic gallstones and presents as episodic biliary pain usually in the right upper abdominal quadrant or epigastric area, which can radiate to the right subscapular area, midback or right shoulder. Episodes of biliary pain generally last between 30 minutes and a few hours and episodes may occur daily or every few months. Nausea is common, but vomiting and fevers are not.

DIFFERENTIAL DIAGNOSIS

- Angina pectoris
- Appendicitis
- Bowel obstruction
- Epigastric pain from myocardial infarction
- Gastro-oesophageal reflux
- Irritable bowel syndrome
- Liver disease
- Oesophagitis
- Pancreatitis
- Peptic ulcer disease

Source: Portincasa et al. 2006¹⁵⁶

Risk factors

- Age—increased biliary cholesterol secretion due to a decrease in cholesterol 7- α -hydroxylase activity¹⁵⁷ and decreased biliary salt excretion¹⁵⁸
- Obesity—increased biliary secretion of bile from the liver with cholesterol supersaturation¹⁵⁶
- Females—in pregnancy, endogenous oestrogens linked to increased hepatic cholesterol uptake and synthesis, gallbladder hypomotility and decreased cholesterol 7- α -hydroxylase activity.^{151,155} The risk for women is two to three times that of males of the same age.^{155,159} Women with a BMI over 32 are six times more likely to develop gallstones than women with a BMI over 22¹⁶⁰
- Rapid weight loss and weight cycling and a prolonged fat-restricted diet is thought to exacerbate gallbladder stasis
- Diet—high carbohydrates in the diet¹⁵² and high triglyceride levels in the blood¹⁵³ are linked to gallstone formation
- Dyspepsia—particularly *Helicobacter* species and slow transit time

Conventional treatment¹⁶¹

- An ultrasound is the common diagnostic tool.
- A cholescintigraphy scan is also used.
- If acute cholecystitis is suspected, refer the patient to their general practitioner or a hospital emergency department.
- Current medical treatment for cholelithiasis is surgery. Single incision laparoscopic

cholecystectomy (SILC) is associated with a 90.7% success rate and a 6.1% complication rate.^{162,163}

Key treatment protocols

- Encourage beneficial dietary and lifestyle changes. (See Chapter 3 on wellness.)
- Promote optimal bile formation in the liver with cholerectics such as *Curcuma longa*,¹⁶⁴ *Cynara scolymus* and *Peumus boldo*.
- Promote effective gallbladder motility and function with cholagogues such as *Cynara scolymus*, *Peumus boldo* and *Taraxacum officinale*.
- As a specific for cholelithiasis use the cholerectic and cholagogue *Peumus boldo*.
- Reduce bile and cholesterol reabsorption in the small intestine by reducing cholesterol intake, synthesis and output with niacin (B3),¹⁶⁵ red yeast rice,^{166,167} *Cynara scolymus*,¹⁶⁸ *Taraxacum officinale*,¹⁶⁹ fibre and probiotics.
- Support optimal digestive function. See Chapters 4–6 on the gastrointestinal system.

* There is limited evidence of the role of herbal medicines in the treatment of cholecystitis¹⁷⁰ and cholelithiasis.

Pancreatitis

Pancreatitis is a progressive inflammatory disease characterised by irreversible destruction of exocrine pancreatic tissue.¹⁷¹ Repeated episodes of acute pancreatitis lead to tissue remodelling and fibrosis.¹⁷¹ Pancreatitis can be due to obstruction of the pancreatic duct. Obstruction leads to an overproduction of ROS in pancreatic acinar cells, affecting the mitochondria and inducing apoptosis and necrosis.^{172,173} Alcohol is the most common cause of pancreatitis. Excessive alcohol consumption may cause the deposition of protein plugs in the pancreatic ducts, leading to obstruction. The presence of gallstones account for 25–40% of cases of pancreatitis; gallstone impaction at the ampulla of Vater causes hypertension in the pancreatic duct, initiating inflammation.¹⁷⁴

Autoimmune pancreatitis is a chronic fibroinflammatory disease of the pancreas. There are two main subtypes: Autoimmune type 1 is a multi-organ disease associated with immunoglobulin G4 (IgG4) and may include proximal bile duct strictures, retroperitoneal fibrosis, renal and salivary gland lesions and swelling of the pancreas. Autoimmune type 2 is a pancreas-specific disorder without systemic involvement.¹⁷⁵

Pancreatitis usually presents with abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back). Serum lipase or amylase activity elevated more than three times upper limit of normal (ULN) is a common finding. Characteristic findings of acute pancreatitis are revealed on contrast-enhanced computed tomography and magnetic resonance imaging or transabdominal ultrasonography.¹⁷⁶ The most common clinical presentation of chronic pancreatitis is midepigastric postprandial pain that radiates to the back that is relieved by sitting upright or leaning forwards.¹⁷⁷ Steatorrhoea, malabsorption, vitamin deficiencies (A, D, E, K, B12), diabetes, weight loss or obstructive jaundice may be present.^{177,178}

Risk factors

- Excessive alcohol consumption—leads to endoplasmic reticulum stress and abnormal unfolded protein responses in pancreas, up-regulation of autophagy and ROS¹⁷⁹
- Cholelithiasis
- Abdominal trauma

DIFFERENTIAL DIAGNOSIS

- Acute cholecystitis
- Acute pancreatitis
- Intestinal ischaemia or infarction
- Obstruction of the common bile duct
- Pancreatic cancer
- Peptic ulcers or gastritis
- Renal insufficiency

Source: Nair et al. 2007¹⁷⁷

- Hyperlipidaemia
- Viral infections
- Medications (azathioprine, thiazides and oestrogens)
- Obesity and smoking increase the risk of progression to severe pancreatitis¹⁸⁰
- Genetics—patients with mutations in genes linked to cationic and anionic trypsinogen, serine protease inhibitor Kazal 1, cystic fibrosis transmembrane conductance regulator, chymotrypsinogen C and calcium-sensing receptor have been shown to be at increased risk of pancreatitis¹⁸⁰
- Environmental (petrochemical fumes)¹⁷⁸
- Untreated acute pancreatitis
- Possible autoimmune factor
- HIV/AIDS (comorbid factors and HAART)¹⁸¹

Conventional treatment

- Autoimmune pancreatitis: corticosteroids¹⁷⁵
- Strong opioids for acute pain
- Removal of gallstones
- Antimicrobials—broad-spectrum antibiotics
- No effective treatment for chronic pancreatitis pain
- Acute: restoration of blood volume and electrolyte balance, replace fluids and minimise pancreatic ischaemia¹⁸⁰
- Enteral feeding¹⁸⁰ to support/avoid malnutrition and development of chronic pancreatitis
- If pancreatitis with hypertriglyceridaemia: weight loss, exercise, blood sugar control, lipid-restriction diet

Key treatment protocols

- *Encourage beneficial dietary and lifestyle changes.* Cease alcohol and tobacco use. Eat low-fat and small meals.¹⁷⁷ (See Chapter 3 on wellness.)
- *Reduce oxidative stress and pain.* Daily antioxidant supplementation of 600 mcg selenium, 0.54 g ascorbic acid, 9000 IU beta-carotene, 270 IU alpha-tocopherol and 2 g methionine was effective in the reduction of pain and oxidative stress of chronic pancreatitis.¹⁷⁸
- *Reduce inflammation.* In experimental pancreatitis (rat model) curcumin reduced inflammation via inhibition of NF-kappa-B and activator protein-1,¹⁸² and *Taraxacum officinale* reduced IL-6 and TNF- α levels in acute pancreatitis.¹⁸³ A TCM formulation targeting pancreatitis contained: *Bupleurum falcatum* (anti-inflammatory), *Glycyrrhiza glabra* (anti-inflammatory and secretin-stimulating), *Panax ginseng* (tonic and free radical scavenging antioxidant) and *Paeonia lactiflora* (proton-pump inhibition). This herbal combination improved pancreatic ischaemia.¹⁸⁴

Table 7.2
Review of the major evidence for liver disease

Intervention	Mechanisms of action	Literature	Summary of results	Comment
Realsil: Silybin 94 mg, phosphatidylcholine 194 mg and α -tocopherol 30 mg	Inhibits and scavenges free radicals; protects lipid membranes; regulates cell signalling pathways involved in obesity and insulin resistance; reduces cell migration, TGF-beta-induced synthesis of procollagen type I and secretion of MMP-2 Phosphatidylcholine protects against oxidative stress-mediated liver damage	Loguerico et al. 2012 ¹⁸⁵	Significant normalisation of ALT, AST and GGT over 12 months Blood glucose was 31% lower in the treated group compared with placebo	Realsil significantly reduced liver inflammation and improved dysglycaemia in NAFLD patients without increases in body weight
<i>Silybum marianum</i> (active isolate: silibinin)	Antiviral, antioxidant, anti-inflammatory, hepatoprotective and antifibrotic effects	Fried et al. 2012 ¹⁸⁶ Guedj et al. 2012 ¹⁸⁷ Kim et al. 2012 ¹⁸⁸ Polyak et al. 2010 ¹⁸⁹	A range of studies have revealed activities that may be beneficial in liver dysfunction and disease including reduced inflammatory cytokines activity: IL-4, IL-10, TNF- α , IFN- γ , VEGF-A, TGF- β and NF- κ B activity Silibinin has prevented viral infection Silibinin inhibited TGF- β induced <i>de novo</i> synthesis of pro-collagen I	Intravenous use of silibinin is promising as an antiviral in HCV ⁴⁵
<i>Scutellaria baicalensis</i> (active isolate: baicalin)	Baicalin ameliorates ischaemia/reperfusion-induced hepatocellular damage by suppressing TLR4-mediated inflammatory responses in ALD ⁶¹	Guo et al. 2009 ⁶⁰ Kim et al. 2012 ⁶¹	Results have found baicalin reduces dyslipidaemia, hepatic lipid accumulation and visceral fat mass <i>in vivo</i> , improves hepatic steatosis ⁶⁰ Reduced serum ALT, TNF- α and IL-6 in alcoholic fatty liver	The antioxidant and anti-inflammatory actions of baicalin and <i>Scutellaria baicalensis</i> make it a very useful clinical tool in NAFLD ⁶⁰ and ALD ⁶¹
<i>Curcuma longa</i>	Shown in a range of studies to have antioxidant, anti-inflammatory and anti-fibrotic actions	Ak et al. 2008 ⁹⁰ Honda et al. 2006 ⁴⁶	Antioxidant, radical scavenging and metal chelating effects in animal models Prevented thioacetamide-induced cirrhosis, and hepatic fibrosis, inhibited hepatic stellate cell (HSC) activation Suppressed connective tissue growth factor expression in HSC activation	<i>Curcuma longa</i> reduces liver injury through down-regulation of inflammatory processes ⁹¹

Continued

Table 7.2
Review of the major evidence for liver disease (continued)

Intervention	Mechanisms of action	Literature	Summary of results	Comment
<i>Cynara scolymus</i>	Shown in a range of studies to have antioxidant, anti-inflammatory, choleric and hepatoprotective actions, which may be of benefit for a range of liver conditions	Speroni et al. 2003 ⁷⁵ Qiang et al. 2012 ¹⁶⁸	Normalisation of AST and ALT Reduction of histological changes and accumulation of triglycerides ⁷⁵ Lowered hamster plasma cholesterol levels by a mechanism involving the greater excretion of fecal bile acids and neutral sterols after feeding for 42 days ¹⁶⁸	Lowers cholesterol and triglyceride levels through stimulating bile production and flow
<i>Glycyrrhiza glabra</i>	Shown in a range of studies to have several beneficial actions for liver conditions including antiviral, anti-inflammatory and hepatoprotective effects	Hajiaghahmohammadi et al. 2012 ⁶² Wu et al. 2008 ⁶³ Rhee et al. 2012 ⁶⁴ Wang et al. 2013 ¹⁹²	Lowered ALT and AST Prevented lipotoxicity and regulated apoptosis Reversed FFA-induced mitochondrial membrane depolarisation in HepG2 cells	Glycyrrhiza's anti-inflammatory and protective actions have significant benefits in treating NAFLD via altering gene expressions pathways seen in fibrosis and reducing hepatic inflammation
<i>Schisandra chinensis</i>	Shown in a range of studies to have antioxidant, hepatoprotective, antiobesity and antidiabetic actions, which may benefit several liver conditions	Pan et al. 2008 ⁷⁶ Park et al. 2012 ¹⁹³	Decreased hepatic total cholesterol and triglyceride levels (by up to 50% and 52%, respectively) in hypercholesterolaemic mice ⁷⁶ Antiobesity action: reduced the accumulation of cellular triglycerides and induced inhibited differentiation and adipogenesis in 3T3-L1 cells in high-fat diet rats ¹⁹¹	Hepatoprotective, especially in terms of lipid metabolism

Continued

Table 7.2
Review of the major evidence for liver disease (continued)

Intervention	Mechanisms of action	Literature	Summary of results	Comment
Alpha-lipoic acid 300–600 mg/day	Improves glucose uptake via up-regulation of GLUT4 receptors Antioxidant—scavenger and up-regulation of endogenous antioxidants via Nrf2/ARE Antifibrotic via inhibition of TGF-β and anti-inflammatory via inhibition of TNF-α induced NF-κB	Kaya-Dagistanli et al. 2013 ¹⁹⁴ Castro et al. 2012 ⁷¹ Hultberg et al. 2006 ¹⁹⁵ Min et al. 2010 ¹⁹⁶ Petersen Shay et al. 2008 ¹⁹⁷ Kim et al. 2004 ¹⁹⁸	Antidiabetic, antihyperlipidaemic, antioxidant, anti-inflammatory, antifibrotic	Decrease in fatty degeneration, inflammation and cell vacuolisation in hepatocytes
L-carnitine	Modulator of fatty acid transport and oxidation Improves beta-oxidation through protection and stimulation of mitochondrial function	Meta-analysis NAFLD Musso et al. 2010 ¹⁹⁹	Improves insulin sensitivity, modulates lipid profiles, glucose metabolism, oxidative stress and is anti-inflammatory and antifibrotic	Improves insulin sensitivity and promotes beta-oxidation

KEY POINTS

- There is a cyclic relationship between metabolic syndrome and liver disease.
- Oxidative stress and inflammation drives pathology in liver disease and pancreatitis. This reduces liver and pancreatic function with systemic consequences for health.
- Effective detoxification can regulate hormones and have anti-carcinogenic effects through inhibition of phase I and induction of phase II enzymes.^{95,87}
- Conventional treatment for NAFLD, NASH, ALD and HCV are either lacking or can have unpleasant side effects, therefore an adjunct naturopathic protocol that can attenuate disease progression and side effects is an essential element of treatment.

FURTHER READING

- Keating SE et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. 2012;57(1):157–66.
- Musso G et al. A meta-analysis of randomised trials for the treatment of NAFLD. *Hepatology* 2010;52:79–104.
- Smith BW and Adams L. Non-alcoholic fatty liver disease. *Critical Reviews in Clinical Laboratory Sciences* 2011;48(3):97–113.
- Wang X, Zhang A, Sun H. Recent Advances in Natural Products from Plants for Treatment of Liver Diseases. *European Journal of Medicinal Chemistry*. 2013.
- Yilmaz Y. Review article: fructose in NAFLD. *Alimentary Pharmacology and Therapeutics* 2012;35:1135–44.

Acknowledgments: Grateful acknowledgment goes to research assistants Rhoslyn Humphreys and Hannah Boyd. This chapter contains material authored by Jon Wardle, which was previously in the *Endometriosis* chapter in the first edition.

REFERENCES

1. Mosely RH. Function of the normal liver. In: O'Grady JG, Lake JR, Howdle PD, editors. *Comprehensive clinical hepatology*. London: Harcourt Publishers Limited; 2000. pp 3.1–16.
2. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature*. 2000;408(6809):239–47.
3. Kung G, Konstantinidis K, Kitsis RN. Programmed necrosis, not apoptosis, in the heart. *Circ Res*. 2011;108(8):1017–36.
4. Medina-Santillan R, Lopez-Velazquez JA, Chavez-Tapia N, Torres-Villalobos G, Uribe M, Mendez-Sanchez N. Hepatic manifestations of metabolic syndrome. *Diabetes/ metabolism research and reviews*. 2013 10.1002/dmrr.2410.
5. Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. *J Nutr Biochem*. 2007;18(3):184–95.
6. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. *J Hepatol*. 2008;48 Suppl 1:S104–12.
7. Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2008;28(1):2–12.
8. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. *J Gastroenterol Hepatol*. 2007;22(6):778–87.
9. Smith BW, Adams LA. Non-alcoholic fatty liver disease. *Crit Rev Clin Lab Sci*. 2011;48(3):97–113.
10. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. *Proc Nutr Soc*. 2010;69(2):211–20.
11. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. *Hepatology*. 2011;54(4):1208–16.
12. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. *Hepatology*. 2010;52(3):913–24.
13. Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, et al. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. *Psychosomatics*. 2011;52(2):127–32.
14. Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes M, Bertrand-Michel J, et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. *J Clin Invest*. 2012;122(6):2176–94.
15. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *The Journal of Clinical Investigation*. 2005;115(5):1343–51.

16. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. *Hepatology*. 2010;52(1):370–81.
17. Pattullo V, Douglas MW, George J. Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? *Expert Rev Gastroenterol Hepatol*. 2011;5(2):265–77.
18. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. *World J Gastroenterol*. 2010;16(42):5286–96.
19. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. *Hepatology*. 2012;56(2):605–13.
20. Kalhan SC, Edmison J, Marczewski S, Dasarathy S, Gruca LL, Bennett C, et al. Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. *Clin Sci (Lond)*. 2011;121(4):179–89.
21. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther*. 2011;34(3):274–85.
22. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology*. 2005;129(1):113–21.
23. Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. *J Hepatol*. 2011;54(4):753–9.
24. Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. *Drugs*. 2013;73(1):1–14.
25. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis – a systematic review and meta analysis. *J Hepatol*. 2011;55(6):1383–90.
26. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol*. 2012;57(1):157–66.
27. Mayes PA. Intermediary metabolism of fructose. *The American Journal of Clinical Nutrition*. 1993;58(5 Suppl):754S–65S.
28. Yki-Jarvinen H. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. *Curr Opin Clin Nutr Metab Care*. 2010;13(6):709–14.
29. Kohli R, Kirby M, Xanthakos SA, Sofic S, Feldstein AE, Saxena V, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. *Hepatology*. 2010;52(3):934–44.
30. Song M, Schuschke DA, Zhou Z, Chen T, Pierce WM, Jr., Wang R, et al. High fructose feeding induces copper deficiency in Sprague-Dawley rats: a novel mechanism for obesity related fatty liver. *J Hepatol*. 2012;56(2):433–40.
31. Garcia-Caraballo SC, Comhair TM, Verheyen F, Gaemers I, Schaap FG, Houten SM, et al. Prevention and reversal of hepatic steatosis with a high-protein diet in mice. *Biochim Biophys Acta*. 2013;1832(5):685–95.
32. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. *Gastroenterology*. 2009;136(5):1552–60.
33. Somi MH, Rezaeifar P, Ostad Rahimi A, Moshrefi B. Effects of low dose zinc supplementation on biochemical markers in non-alcoholic cirrhosis: a randomized clinical trial. *Archives of Iranian Medicine*. 2012;15(8):472–6.
34. Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. *Diabetes*. 2012;61(11):2787–95.
35. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. *Gut*. 2011;60(9):1278–83.
36. Rodriguez-Hernandez H, Cervantes-Huerta M, Rodriguez-Moran M, Guerrero-Romero F. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. *Ann Hepatol*. 2011;10(4):486–92.
37. Tilg H, Moschen A. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. *Minerva Gastroenterol Dietol*. 2010;56(2):159–67.
38. Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. *Journal of Gastroenterology and Hepatology*. 2006;21(1 Pt 1):191–8.
39. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. *The American Journal of Gastroenterology*. 2011;106(3):460–8; quiz 469.
40. Fealy CE, Haus JM, Solomon TP, Pagadala M, Flask CA, McCullough AJ, et al. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. *J Appl Physiol*. 2012;113(1):1–6.
41. Simpson KA, Singh MA. Effects of exercise on adiponectin: a systematic review. *Obesity*. 2008;16(2):241–56.
42. Mann DA, Marra F. Fibrogenic signalling in hepatic stellate cells. *J Hepatol*. 2010;52(6):949–50.
43. Coker RH, Williams RH, Yeo SE, Kortebein PM, Bodenner DL, Kern PA, et al. The impact of exercise training compared to caloric restriction on hepatic and peripheral insulin resistance in obesity. *The Journal of Clinical Endocrinology and Metabolism*. 2009;94(11):4258–66.
44. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Rise P, Galli C, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. *Arch Dis Child*. 2011;96(4):350–3.
45. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med*. 2010;362(18):1675–85.
46. Honda S, Aoki F, Tanaka H, Kishida H, Nishiyama T, Okada S, et al. Effects of ingested turmeric oleoresin on glucose and lipid metabolisms in obese diabetic mice: a DNA microarray study. *J Agric Food Chem*. 2006;54(24):9055–62.
47. Polyak SJ, Oberlies NH, Pecher EI, Dahari H, Ferenci P, Pawlowsky JM. Silymarin for HCV infection. *Antivir Ther*. 2013;18(2):141–7.
48. Son TG, Camandola S, Mattson MP. Hormetic dietary phytochemicals. *Neuromolecular Med*. 2008;10(4):236–46.
49. Ristow M, Schmeisser S. Extending life span by increasing oxidative stress. *Free Radical Biology & Medicine*. 2011;51(2):327–36.
50. Ristow M, Zarse K. How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis). *Exp Gerontol*. 2010;45(6):410–18.
51. Villanueva C, Kross RD. Antioxidant-induced stress. *Int J Mol Sci*. 2012;13(2):2091–109.
52. Surh YJ. Xenohormesis mechanisms underlying chemopreventive effects of some dietary phytochemicals. *Ann N Y Acad Sci*. 2011;1229:1–6.

53. Kim J, Cha YN, Surh YJ. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. *Mutat Res.* 2010;690(1–2):12–23.
54. Chlopčikova S, Psotova J, Miketova P, Simanek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. *Phytother Res.* 2004;18(2):107–10.
55. Aghazadeh S, Amini R, Yazdanparast R, Ghaffari SH. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. *Exp Toxicol Pathol.* 2011;63(6):569–74.
56. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. *Gastroenterology.* 2007;132(5):1925–36.
57. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. *Annu Rev Pathol.* 2011;6:425–56.
58. Trappolieri M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, et al. Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. *J Hepatol.* 2009;50(6):1102–11.
59. Lin J, Zheng S, Chen A. Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress. *Lab Invest.* 2009;89(12):1397–409.
60. Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, Du ZY, et al. Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. *Acta Pharmacol Sin.* 2009;30(11):1505–12.
61. Kim SJ, Lee SM. Effect of baicalin on toll-like receptor 4-mediated ischemia/reperfusion inflammatory responses in alcoholic fatty liver condition. *Toxicol Appl Pharmacol.* 2012;258(1):43–50.
62. Hajiaghahmohammadi AA, Ziaee A, Samimi R. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. *Phytother Res.* 2012;26(9):1381–4.
63. Wu X, Zhang L, Gurley E, Studer E, Shang J, Wang T, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetic acid through lysosomal and mitochondrial pathways. *Hepatology.* 2008;47(6):1905–15.
64. Rhee SD, Kim CH, Park JS, Jung WH, Park SB, Kim HY, et al. Carbenoxolone prevents the development of fatty liver in C57BL/6-Lep ob/ob mice via the inhibition of sterol regulatory element binding protein-1c activity and apoptosis. *Eur J Pharmacol.* 2012;691(1–3):9–18.
65. Kar P, Laight D, Rooprai HK, Shaw KM, Cummings M. Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. *Diabet Med.* 2009;26(5):526–31.
66. Khoshbaten M, Aliasgarzadeh A, Masnadi K, Farhang S, Tarzamani MK, Babaei H, et al. Grape seed extract to improve liver function in patients with nonalcoholic fatty liver change. *Saudi J Gastroenterol.* 2010;16(3):194–7.
67. White DL, Richardson PA, Al-Saadi M, Fitzgerald SJ, Green L, Amaratunge C, et al. Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. *Dig Dis Sci.* 2011;56(6):1835–47.
68. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. *Free Radic Biol Med.* 2012;52(1):59–69.
69. Lim CY, Jun DW, Jang SS, Cho WK, Chae JD, Jun JH. Effects of carnitine on peripheral blood mitochondrial DNA copy number and liver function in non-alcoholic fatty liver disease. *Korean J Gastroenterol.* 2010;55(6):384–9.
70. Jun DW, Cho WK, Jun JH, Kwon HJ, Jang KS, Kim HJ, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. *Liver Int.* 2011;31(9):1315–24.
71. Castro MC, Massa ML, Schinella G, Gagliardino JJ, Francini F. Lipoic acid prevents liver metabolic changes induced by administration of a fructose-rich diet. *Biochim Biophys Acta.* 2012;1830(1):226–32.
72. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. *Liver Int.* 2010;30(7):1019–26.
73. Cichoż-Lach H, Celinski K, Konturek PC, Konturek SJ, Slomka M. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. *J Physiol Pharmacol.* 2010;61(5):577–80.
74. Di Pierro F, Villanova N, Agostini F, Marzocchi R, Soverini V, Marchesini G. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. *Diabetes Metab Syndr Obes.* 2012;5:213–17.
75. Speroni E, Cervellati R, Govoni P, Guizzardi S, Renzulli C, Guerra MC. Efficacy of different *Cynara scolymus* preparations on liver complaints. *J Ethnopharmacol.* 2003;86(2–3):203–11.
76. Pan SY, Dong H, Zhao XY, Xiang CJ, Fang HY, Fong WF, et al. Schisandrin B from *Schisandra chinensis* reduces hepatic lipid contents in hypercholesterolaemic mice. *J Pharm Pharmacol.* 2008;60(3):399–403.
77. Anstee QM, Day CP. S-adenosylmethionine (SAME) therapy in liver disease: a review of current evidence and clinical utility. *J Hepatol.* 2012;57(5):1097–109.
78. Khoshbaten M, Aliasgarzadeh A, Masnadi K, Tarzamani MK, Farhang S, Babaei H, et al. N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease. *Hepat Mon.* 2010;10(1):12–16.
79. Huisman EJ, Trip EJ, Siersema PD, van Hoek B, van Erpecum KJ. Protein energy malnutrition predicts complications in liver cirrhosis. *Eur J Gastroenterol Hepatol.* 2011;23(11):982–9.
80. Chadalavada R, Sappati Biyyani RS, Maxwell J, Mullen K. Nutrition in hepatic encephalopathy. *Nutr Clin Pract.* 2010;25(3):257–64.
81. Ambuhl PM. Protein intake in renal and hepatic disease. *Int J Vitam Nutr Res.* 2011;81(2–3):162–72.
82. Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. *Hepatology.* 2008;48(2):557–66.
83. Mukherjee PK, Ponnusankar S, Pandit S, Hazam PK, Ahmmed M, Mukherjee K. Botanicals as medicinal food and their effects on drug metabolizing enzymes. *Food Chem Toxicol.* 2011;49(12):3142–53.
84. Talalay P. Mechanisms of induction of enzymes that protect against chemical carcinogenesis. *Advances in Enzyme Regulation.* 1989;28:237–50.
85. Salmond S. The hepatobiliary system. In: Hechtman L, editor. *Clinical Naturopathic Medicine.* Australia: Elsevier; 2011. pp 210–79.
86. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. *Clinical Pharmacokinetics.* 1996;31(1):47–64.
87. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. *Toxicology in vitro: an international journal published in association with BIBRA.* 2006;20(2):187–210.

88. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. *Journal of the American Medical Association*. 2006;295(10):1135–41.
89. Hornsby LB, Hester EK, Donaldson AR. Potential interaction between warfarin and high dietary protein intake. *Pharmacotherapy*. 2008;28(4):536–9.
90. Cermak R. Effect of dietary flavonoids on pathways involved in drug metabolism. *Expert Opinion on Drug Metabolism & Toxicology*. 2008;4(1):17–35.
91. Horváthová E, Slameňová D, Navarová J. Administration of rosemary essential oil enhances resistance of rat hepatocytes against DNA-damaging oxidative agents. *Food Chemistry*. 2010;123(1):151–6.
92. Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and Seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. *Life Sciences*. 2002;71(10):1149–60.
93. Wason S, DiGiacinto JL, Davis MW. Effects of grapefruit and Seville orange juices on the pharmacokinetic properties of colchicine in healthy subjects. *Clinical therapeutics*. 2012;34(10):2161–73.
94. Johri RK. Cuminum cyminum and Carum carvi: An update. *Pharmacognosy reviews*. 2011;5(9):63–72.
95. Konsue N, Ioannides C. Modulation of carcinogen-metabolising cytochromes P450 in human liver by the chemopreventive phytochemical phenethyl isothiocyanate, a constituent of cruciferous vegetables. *Toxicology*. 2010;268(3):184–90.
96. Munday R, Munday CM. Induction of phase II enzymes by aliphatic sulfides derived from garlic and onions: an overview. *Methods in enzymology*. 2004;382:449–56.
97. Chen C, Pung D, Leong V, Hebbar V, Shen G, Nair S, et al. Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor Nrf2: effect of chemical structure and stress signals. *Free Radical Biology and Medicine*. 2004;37(10):1578–90.
98. Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. *Drug Metabolism and Disposition: the biological fate of chemicals*. 2004;32(12):1351–8.
99. Jeong HG, You HJ, Park SJ, Moon AR, Chung YC, Kang SK, et al. Hepatoprotective effects of 18beta-glycyrrhetic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. *Pharmacological Research: The official journal of the Italian Pharmacological Society*. 2002;46(3):221–7.
100. Subehan, Zaidi SF, Kadota S, Tezuka Y. Inhibition on human liver cytochrome P450 3A4 by constituents of fennel (*Foeniculum vulgare*): identification and characterization of a mechanism-based inactivator. *Journal of Agricultural and Food Chemistry*. 2007;55(25):10162–7.
101. Kiruthiga PV, Karthikeyan K, Archunan G, Karutha Pandian S, Pandima Devi K. Silymarin prevents benzo(a) pyrene-induced toxicity in Wistar rats by modulating xenobiotic-metabolizing enzymes. *Toxicology and Industrial Health*. (Impact Factor: 1.42). 02/2013; doi:10.1177/074823371347552
102. Balstad TR, Carlsen H, Myhrstad MC, Kolberg M, Reiersen H, Gilen L, et al. Coffee, broccoli and spices are strong inducers of electrophile response element-dependent transcription in vitro and in vivo – studies in electrophile response element transgenic mice. *Molecular Nutrition & Food Research*. 2011;55(2):185–97.
103. Nirmala K, Krishna PT, Polasa K. Modulation of xenobiotic metabolism in ginger (*Zingiber officinale* Roscoe) fed rats. *Int J Nutr Metabolism*. 2010;2(3):56–62.
104. Munday R, Munday CM. Induction of phase II enzymes by 3H-1,2-dithiole-3-thione: dose-response study in rats. *Carcinogenesis*. 2004;25(9):1721–5.
105. Lee SB, Kim CY, Lee HJ, Yun JH, Nho CW. Induction of the phase II detoxification enzyme NQO1 in hepatocarcinoma cells by lignans from the fruit of *Schisandra chinensis* through nuclear accumulation of Nrf2. *Planta Medica*. 2009;75(12):1314–18.
106. Son TG, Camandola S, Mattson MP. Hormetic dietary phytochemicals. *Neuromolecular Med*. 2008;10(4):236–46.
107. Dietz BM, Hagos GK, Eskra JN, Wijewickrama GT, Anderson JR, Nikolic D, et al. Differential regulation of detoxification enzymes in hepatic and mammary tissue by hops (*Humulus lupulus*) in vitro and in vivo. *Molecular Nutrition and Food Research*. 2013;57(6):1055–66.
108. Moon A, Kim SH. Effect of Glycyrrhiza glabra roots and glycyrrhizin on the glucuronidation in rats. *Planta Medica*. 1997;63(2):115–19.
109. Zegura B, Dobnik D, Niderl MH, Filipic M. Antioxidant and antigenotoxic effects of rosemary (*Rosmarinus officinalis* L.) extracts in *Salmonella typhimurium* TA98 and HepG2 cells. *Environ Toxicol Pharmacol*. 2011;32(2):296–305.
110. Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M, et al. Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. *J Gastroenterol Hepatol*. 2000;15 Suppl:D20–5.
111. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. *Clinical Pharmacology and Therapeutics*. 2002;72(3):276–87.
112. Mullerova D, Kopecky J. White adipose tissue: storage and effector site for environmental pollutants. *Physiological Research / Academia Scientiarum Bohemoslovaca*. 2007;56(4):375–81.
113. Stiefelhagen P. [Functional disorders call for total therapy – Kneipp's hydrotherapy instead of psychopharmaceuticals]. *MMW Fortschritte der Medizin*. 2005;147(18):4–6, 8.
114. Krop J. Chemical sensitivity after intoxication at work with solvents: response to sauna therapy. *J Altern Complement Med*. 1998;4(1):77–86.
115. Chambaz A, Meirim I, Decombaz J. Urinary caffeine after coffee consumption and heat dehydration. *International Journal of Sports Medicine*. 2001;22(5):366–72.
116. Hannuksela ML, Ellahham S. Benefits and risks of sauna bathing. *The American Journal of Medicine*. 2001;110(2):118–26.
117. Duncan K, Harris S, Ardies CM. Running exercise may reduce risk for lung and liver cancer by inducing activity of antioxidant and phase II enzymes. *Cancer letters*. 1997;116(2):151–8.
118. Yiamouyiannis CA, Sanders RA, Watkins JB, 3rd, Martin BJ. Chronic physical activity: hepatic hypertrophy and increased total biotransformation enzyme activity. *Biochem Pharmacol*. 1992;44(1):121–7.
119. Cohen M. 'Detox': science or sales pitch? *Australian Family Physician*. 2007;36(12):1009–10.
120. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. *Eur Rev Med Pharmacol Sci*. 2011;15(9):1090–5.
121. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. *Dig Dis Sci*. 2012;57(2):545–53.
122. Ashrafi M, Modabbernia A, Dalir M, Taslimi S, Karami M, Ostovaneh MR, et al. Predictors of mental and physical

- health in non-cirrhotic patients with viral hepatitis: a case control study. *Journal of Psychosomatic Research*. 2012;73(3):218–24.
123. Lee K, Otgonsuren M, Younoszai Z, Mir HM, Younoszi ZM. Association of chronic liver disease with depression: a population-based study. *Psychosomatics*. 2013;54(1):52–9.
 124. Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. *J Clin Virol*. 2003;26(2):171–84.
 125. Hoofnagle JH. Course and outcome of hepatitis C. *Hepatology*. 2002;36(5 Suppl 1):S21–9.
 126. Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. *Gut*. 2001;49(3):423–30.
 127. Farrell GC. Chronic viral hepatitis. *Med J Aust*. 1998;168(12):619–26.
 128. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. *Gastroenterology*. 2008;134(6):1699–714.
 129. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*. 2004;140(5):346–55.
 130. The Kirby Institute. 2011 HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report. Sydney 2011.
 131. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. *N Engl J Med*. 2010;362(14):1292–303.
 132. Pawlotsky JM. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. *Gastroenterology*. 2011;140(3):746–54.
 133. Lewis H, Cunningham M, Foster G. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. *Best Pract Res Clin Gastroenterol*. 2012;26(4):471–85.
 134. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *N Engl J Med*. 2013;368(1):34–44.
 135. Dusheiko G, Wedemeyer H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. *Gut*. 2012;61(12):1647–52.
 136. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. *J Clin Invest*. 1996;98(3):706–14.
 137. Semmo N, Klenerman P. CD4+ T cell responses in hepatitis C virus infection. *World J Gastroenterol*. 2007;13(36):4831–8.
 138. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. *Immunity*. 1999;10(4):439–49.
 139. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend B, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. *J Exp Med*. 2000;191(9):1499–512.
 140. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. *Nature*. 2005;436(7053):946–52.
 141. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. *Hepatology*. 1997;25(2):449–58.
 142. Yang X, Huang S, Chen J, Song N, Wang L, Zhang Z, et al. Evaluation of the adjuvant properties of *Astragalus membranaceus* and *Scutellaria baicalensis* GEORGI in the immune protection induced by UV-attenuated *Toxoplasma gondii* in mouse models. *Vaccine*. 2010;28(3):737–43.
 143. Kapai NA, Anisimova NY, Kiselevskii MV, Sitdikova SM, Slavetskaya MB. Selective cytokine-inducing effects of low dose *Echinacea*. *Bull Exp Biol Med*. 2011;150(6):711–13.
 144. Chowdhury S, Mukherjee T, Mukhopadhyay R, Mukherjee B, Sengupta S, Chattopadhyay S, et al. The lignan niranthin poisons *Leishmania donovani* topoisomerase IB and favours a Th1 immune response in mice. *EMBO Mol Med*. 2012;4(10):1126–43.
 145. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. *Gastroenterology*. 2008;135(5):1561–7.
 146. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. *J Hepatol*. 2010;52(6):951–2.
 147. Romano M, Vacante M, Cristaldi E, Colonna V, Gargante MP, Cammalleri L, et al. L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. *Dig Dis Sci*. 2008;53(4):1114–21.
 148. Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. *Transpl Int*. 2011;24(1):43–50.
 149. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falletti E, Fornasiere E, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. *Hepatology*. 2011;53(4):1118–26.
 150. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. *Hepatology*. 2010;51(4):1158–67.
 151. Toouli J, Wright TA. Gallstones. *Med J Aust*. 1998;169(3):166–71.
 152. Cuevas A, Miquel JF, Reyes MS, Zanlungo S, Nervi F. Diet as a risk factor for cholesterol gallstone disease. *J Am Coll Nutr*. 2004;23(3):187–96.
 153. Jonkers IJ, Smelt AH, Ledebor M, Hollum ME, Biemond I, Kuipers F, et al. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. *Gut*. 2003;52(1):109–15.
 154. Lammert F, Miquel JF. Gallstone disease: from genes to evidence-based therapy. *J Hepatol*. 2008;48 Suppl 1: S124–35.
 155. Kalloo AN, Kantsevov SV. Gallstones and biliary disease. *Prim Care*. 2001;28(3):591–606, vii.
 156. Portincasa P, Moschetta A, Petruzzelli M, Palasciano G, Di Ciaula A, Pezzolla A. Gallstone disease: Symptoms and diagnosis of gallbladder stones. *Best Pract Res Clin Gastroenterol*. 2006;20(6):1017–29.
 157. Donovan JM. Physical and metabolic factors in gallstone pathogenesis. *Gastroenterology Clinics of North America*. 1999;28(1):75–97.
 158. Grunhage F, Lammert F. Gallstone disease. Pathogenesis of gallstones: A genetic perspective. *Best Practice & Research Clinical Gastroenterology*. 2006;20(6):997–1015.

159. Shaffer EA. Gallstone disease: Epidemiology of gallbladder stone disease. *Best Practice & Research Clinical Gastroenterology*. 2006;20(6):981–96.
160. Mendez-Sanchez N, Zamora-Valdes D, Chavez-Tapia NC, Uribe M. Role of diet in cholesterol gallstone formation. *Clin Chim Acta*. 2007;376(1–2):1–8.
161. Kiewiet JJ, Leeuwenburgh MM, Bipat S, Bossuyt PM, Stoker J, Boermeester MA. A systematic review and meta-analysis of diagnostic performance of imaging in acute cholecystitis. *Radiology*. 2012;264(3):708–20.
162. Antoniou SA, Pointner R, Granderath FA. Single-incision laparoscopic cholecystectomy: a systematic review. *Surg Endosc*. 2011;25(2):367–77.
163. Joseph M, Phillips MR, Farrell TM, Rupp CC. Single incision laparoscopic cholecystectomy is associated with a higher bile duct injury rate: a review and a word of caution. *Ann Surg*. 2012;256(1):1–6.
164. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. *AAPS J*. 2013;15(1):195–218.
165. Hamoud S, Kaplan M, Meilin E, Hassan A, Torgovicky R, Cohen R, et al. Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. *Am J Med Sci*. 2013;345(3):195–9.
166. Yang CW, Mousa SA. The effect of red yeast rice (*Monascus purpureus*) in dyslipidemia and other disorders. *Complement Ther Med*. 2012;20(6):466–74.
167. Feuerstein JS, Bjerke WS. Powdered red yeast rice and plant stanols and sterols to lower cholesterol. *J Diet Suppl*. 2012;9(2):110–15.
168. Qiang Z, Lee SO, Ye Z, Wu X, Hendrich S. Artichoke extract lowered plasma cholesterol and increased fecal bile acids in Golden Syrian hamsters. *Phytother Res*. 2012;26(7):1048–52.
169. Gonzalez-Castejon M, Visioli F, Rodriguez-Casado A. Diverse biological activities of dandelion. *Nutr Rev*. 2012;70(9):534–47.
170. Dong ZY, Wang GL, Liu X, Liu J, Zhu DZ, Ling CQ. Treatment of cholecystitis with Chinese herbal medicines: a systematic review of the literature. *World J Gastroenterol*. 2012;18(14):1689–94.
171. Saurer L, Reber P, Schaffner T, Buchler MW, Buri C, Kappeler A, et al. Differential expression of chemokines in normal pancreas and in chronic pancreatitis. *Gastroenterology*. 2000;118(2):356–67.
172. Gerasimenko OV, Gerasimenko JV. Mitochondrial function and malfunction in the pathophysiology of pancreatitis. *Pflugers Archiv: European Journal of Physiology*. 2012;464(1):89–99.
173. Grigsby B, Rodriguez-Rilo H, Khan K. Antioxidants and chronic pancreatitis: theory of oxidative stress and trials of antioxidant therapy. *Dig Dis Sci*. 2012;57(4):835–41.
174. Everson GT. Biliary and Cholestatic Diseases. In: O'Grady JG, Lake JR, Howdle PD, editors. *Comprehensive Clinical Hepatology*. London: Harcourt Publishers Limited; 2000. pp 26.1–17.
175. Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. *Gastroenterology*. 2010;139(1):140–8; quiz e12–13.
176. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. *Gut*. 2013;62(1):102–11.
177. Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. *American Family Physician*. 2007;76(11):1679–88.
178. Bhardwaj P, Garg PK, Maulik SK, Saraya A, Tandon RK, Acharya SK. A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis. *Gastroenterology*. 2009;136(1):149–59, e2.
179. Ji C. Mechanisms of alcohol-induced endoplasmic reticulum stress and organ injuries. *Biochemistry Research International*. doi: 10.1155/2012/216450.
180. Grant JP. Nutritional support in acute and chronic pancreatitis. *The Surgical Clinics of North America*. 2011;91(4):805–20, viii.
181. Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. *Asian Pac J Trop Biomed*. 2013;3(6):422–5.
182. Gukovsky I, Reyes CN, Vaquero EC, Gukovskaya AS, Pandol SJ. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. *American Journal of Physiology Gastrointestinal and Liver Physiology*. 2003;284(1):G85–95.
183. Seo SW, Koo HN, An HJ, Kwon KB, Lim BC, Seo EA, et al. *Taraxacum officinale* protects against cholecystokinin-induced acute pancreatitis in rats. *World J Gastroenterol*. 2005;11(4):597–9.
184. Motoo Y, Su SB, Xie MJ, Taga H, Sawabu N. Effect of herbal medicine Saiko-keishi-to (TJ-10) on rat spontaneous chronic pancreatitis: comparison with other herbal medicines. *International Journal of Pancreatology: official journal of the International Association of Pancreatology*. 2000;27(2):123–9.
185. Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiramonte M, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. *Free Radic Biol Med*. 2012;52(9):1658–65.
186. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. *JAMA*. 2012;308(3):274–82.
187. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silybinin's modes of action against HCV using viral kinetic modeling. *J Hepatol*. 2012;56(5):
188. Kim M, Yang SG, Kim JM, Lee JW, Kim YS, Lee JI. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. *Int J Mol Med*. 2012;30(3):473–9.
189. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, et al. Identification of hepatoprotective flavonolignans from silymarin. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(13):5995–9.
190. Ak T, Gülçin I. Antioxidant and radical scavenging properties of curcumin. *Chem Biol Interact*. 2008;174(1):27–37.
191. Bruck R, Ashkenazi M, Weiss S, Goldiner I, Shapiro H, Aeed H, et al. Prevention of liver cirrhosis in rats by curcumin. *Liver Int*. 2007;27(3):373–83.
192. Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies. *Dig Liver Dis*. 2013;45(7):543–51.
193. Park HJ, Cho J-Y, Kim MK, Koh P-O, Cho K-W, Kim CH, et al. Anti-obesity effect of *Schisandra chinensis* in 3T3-L1 cells and high fat diet-induced obese rats. *Food Chemistry*. 2012;134(1):227–34.
194. Kaya-Dagistanli F, Tanriverdi G, Altinok A, Ozyazgan S, Ozturk M. The effects of alpha lipoic acid on liver cells damages and apoptosis induced by polyunsaturated fatty acids. *Food Chem Toxicol*. 2013;53:84–93.

195. Hultberg M, Hultberg B. The effect of different antioxidants on glutathione turnover in human cell lines and their interaction with hydrogen peroxide. *Chem Biol Interact.* 2006;163(3):192–8.
196. Min AK, Kim MK, Seo HY, Kim HS, Jang BK, Hwang JS, et al. Alpha-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-beta signaling pathway. *Biochem Biophys Res Commun.* 2010;393(3):536–41.
197. Petersen Shay K, Moreau RF, Smith EJ, Hagen TM. Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. *IUBMB Life.* 2008;60(6):362–7.
198. Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. *Nature Medicine.* 2004;10(7):727–33.
199. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology.* 2010;52(1):79–104.